Fosun Pharmaceutical (02196): Drug registration application for sodium phosphonate injection approved by the State Drug Administration

Zhitongcaijing · 2d ago

Zhitong Finance App News, Fosun Pharmaceutical (02196) issued an announcement. Recently, Guilin Southern Pharmaceutical Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”), was approved by the State Drug Administration for drug registration of sodium phosphonoformate injection (hereinafter referred to as “this drug”). The approved indications are for treatment of (1) cytomegalovirus retinitis in AIDS (AIDS) patients and (2) acyclovir-resistant herpes simplex virus mucosal infections in patients with impaired immune function.

As of November 2025, the Group (i.e. the Company and its holding subsidiaries/units, the same below) has invested approximately RMB 4.98 million (unaudited) in R&D of this drug at this stage.

According to the latest IQVIACHPA data, in 2024, sales of sodium phosphonate injections in China (excluding Hong Kong, Macao and Taiwan) will be approximately RMB 86.4 million.

The drug has now been approved for marketing, which will further enrich the Group's product line.